Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
RIO
-0.3300
The Fort Worth Press - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
USD
-
AED 3.672497
AFN 64.99979
ALL 80.742224
AMD 360.119907
ANG 1.789785
AOA 918.000449
ARS 1547.512201
AUD 1.427114
AWG 1.8
AZN 1.695151
BAM 1.737338
BBD 2.013458
BDT 124.459802
BGN 1.747831
BHD 0.37735
BIF 3010
BMD 1
BND 1.277909
BOB 12.120755
BRL 5.460101
BSD 0.999711
BTN 94.558763
BWP 13.724402
BYN 2.982914
BYR 19600
BZD 2.010562
CAD 1.39706
CDF 2315.000267
CHF 0.816503
CLF 0.02453
CLP 965.430226
CNY 6.67355
CNH 6.67376
COP 3229.36
CRC 454.091218
CUC 1
CUP 23.992112
CVE 98.896657
CZK 21.61525
DJF 177.720122
DKK 6.65239
DOP 60.604398
DZD 135.956026
EGP 54.717302
ERN 15
ETB 164.071845
EUR 0.88999
FJD 2.244198
FKP 0.745268
GBP 0.741965
GEL 2.600226
GGP 0.745268
GHS 11.631305
GIP 0.745268
GMD 74.000096
GNF 8855.000058
GTQ 7.639521
GYD 209.448686
HKD 7.84505
HNL 26.868429
HRK 6.76901
HTG 130.971046
HUF 322.693501
IDR 18110.4
ILS 3.153899
IMP 0.745268
INR 94.51575
IQD 1515.529716
IRR 1883408.502243
ISK 121.579569
JEP 0.745268
JMD 158.455068
JOD 0.709015
JPY 158.401996
KES 129.920112
KGS 87.450166
KHR 4064.827605
KMF 440.999835
KPW 899.999961
KRW 1341.484997
KWD 0.310805
KYD 0.833041
KZT 451.807175
LAK 22506.673299
LBP 89519.744527
LKR 332.641939
LRD 169.939285
LSL 16.455617
LTL 2.952739
LVL 0.60489
LYD 6.409977
MAD 9.765444
MDL 17.929301
MGA 4515.192027
MKD 54.78946
MMK 2099.52083
MNT 3598.087189
MOP 8.077598
MRU 40.663904
MUR 47.090014
MVR 15.455015
MWK 1733.399066
MXN 18.60899
MYR 4.071298
MZN 63.910474
NAD 16.455325
NGN 1346.42026
NIO 36.784529
NOK 9.29659
NPR 151.29402
NZD 1.778304
OMR 0.384501
PAB 0.999773
PEN 3.450426
PGK 4.485918
PHP 63.345497
PKR 276.534117
PLN 3.904405
PYG 6061.763543
QAR 3.644609
RON 4.754098
RSD 104.67979
RUB 81.801499
RWF 1471.012787
SAR 3.756339
SBD 8.051718
SCR 13.701544
SDG 601.500853
SEK 9.731575
SGD 1.27865
SHP 0.745545
SLE 22.909978
SLL 20969.504398
SOS 571.349894
SRD 37.563974
STD 20697.981008
STN 21.763752
SVC 8.747096
SYP 13001.999685
SZL 16.44674
THB 33.593497
TJS 9.221818
TMT 3.51
TND 2.979449
TOP 2.40776
TRY 50.043203
TTD 6.776725
TWD 32.836099
TZS 2649.998018
UAH 45.52523
UGX 4104.021853
UYU 40.19489
UZS 11886.139647
VES 890.0366
VND 25704.5
VUV 119.472328
WST 2.779309
XAF 583.794901
XAG 0.019139
XAU 0.000246069955
XCD 2.70255
XCG 1.801579
XDR 0.707052
XOF 583.794901
XPF 105.938734
YER 236.175008
ZAR 16.39546
ZMK 9001.202271
ZMW 20.274394
ZWL 321.999592
SSP 5745.96484
MXV 2.094656
- India introduces four-layer motor insurance choice from December 15
- Mutual fund returns show shifting leaders across market-cap categories
- BHEL wins Adani Power projects valued at up to ₹28,000 crore
- IndiGo holds talks with Embraer over potential order for 100 aircraft
- India seeks threefold increase in coal stocks to prevent summer power shortages
- Indian companies report mixed second-quarter results on November 4
- Indus Towers expands solar-powered network to 50,000 telecom sites
- KKR secures Indian regulator approval for Gentari Renewables investment
- Equitas Small Finance Bank rebounds after naming interim chief executive
- Bharti Airtel revenue expected to grow at double-digit pace in second quarter
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Details for the presentation are as follows:
Abstract Number: 123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT
For more information, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
H.M.Hernandez--TFWP
